NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Famotidine

Last Revision: October 31, 2018.

Estimated reading time: 1 minute

CASRN: 76824-35-6

Chemical structure

Drug Levels and Effects

Summary of Use during Lactation

Famotidine is used in newborn infants in higher dosages than are transmitted in breastmilk.[1] Famotidine would not be expected to cause any adverse effects in breastfed infants. No special precautions are required.

Drug Levels

Maternal Levels. Eight women who had "recently given birth" (not defined, but apparently within a few days postpartum) were given famotidine 40 mg orally. An average peak breastmilk level of 72 mcg/L occurred 6 hours after the dose.[2] Using the peak milk level data from this study, an exclusively breastfed infant would receive an estimated maximum of 0.01 mg/kg daily with this maternal dosage regimen or less than 2% of the maternal weight-adjusted dosage.

Seven women were given oral famotidine 40 mg daily in 2 or 4 divided doses for 3 days at 12 to 16 weeks postpartum. Average concentrations of famotidine in breastmilk were 53 and 55 mcg/L at 3 and 6 hours after a dose, respectively.[3]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Histamine H2-receptor blockade is known to stimulate prolactin secretion.[4] Oral famotidine usually does not affect serum prolactin levels, but rare cases of hyperprolactinemia and galactorrhea have been reported.[5][6] The prolactin level in a mother with established lactation may not affect her ability to breastfeed.

References

1.
Orenstein SR, Shalaby TM, Devandry SN et al. Famotidine for infant gastro-oesophageal reflux: A multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther. 2003;17(9):1097-107. [PubMed: 12752346]
2.
Courtney TP, Shaw RW, Cedar E et al. Excretion of famotidine in breast milk. Br J Clin Pharmacol. 1988;26:639P. Abstract. PMC: PMC1386642.
3.
Wang X, Zhan Y, Hankins GD et al. Pharmacokinetics of famotidine in pregnant women. Am J Obstet Gynecol. 2011;204:S72-3. Abstract.
4.
Knigge UP. Histaminergic regulation of prolactin secretion. Dan Med Bull. 1990;37:109-24. [PubMed: 2188799]
5.
Delpre G, Lapidot M, Lipchitz A et al. Hyperprolactinaemia during famotidine therapy. Lancet. 1993;342:868. Letter. [PubMed: 8104296]
6.
Guven K, Kelestimur F. Hyperprolactinemia and galactorrhea with standard-dose famotidine therapy. Ann Pharmacother. 1995;29:788. Letter. [PubMed: 8520102]

Substance Identification

Substance Name

Famotidine

CAS Registry Number

76824-35-6

Drug Class

  • Breast Feeding
  • Anti-Ulcer Agents
  • Histamine H2 Antagonists
  • Gastrointestinal Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...